BioMosaics Home

Biomarker development for the early detection of cancer

Product Information - New Antibodies!

anti-human T Cell Factor 1 (TCF-1); clone 7H3

anti-human SPARC affinity-purified rabbit polyclonal

The Glypican-3 ELISA (catalog #s B1500 and B1500R) is being re-developed. Click here for updates.

May 19, 2009 - "EMS mutant spectra generated by multi-parameter flow cytometry", by SB Keysar and M Fox, Mutation Research >>

Authors used flow cytometry mutation assay with CD59, 44, 90, 98, and 151 for detection of GPI-mutants, to generate mutational spectra for EMS and ionizing radiation.

Latest News

April 23, 2009 - BioMosaics and Amorfix Life Sciences Collaborate to develop a bloold test for liver cancer supported by grant from the Ontario Institute for Cancer Research >>

March 26, 2009 - Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer >>

Recent publications

April 29, 2009 - "Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.", by C. Nassar et al., Diagnostic Cytopathology >>

GPC3 is a reliable and more specific immunohistochemical marker than survivin for the diagnosis of HCC in FNAB.

"Our data supports the potentially significant diagnostic utility of GPC3 in FNABs in differentiating primary malignant from benign and preneoplastic liver lesions, and metastatic carcinomas"